0RK Stock Overview
An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Exscientia plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.50 |
| 52 Week High | US$7.70 |
| 52 Week Low | US$3.66 |
| Beta | 0.84 |
| 11 Month Change | 1.35% |
| 3 Month Change | -14.29% |
| 1 Year Change | -21.05% |
| 33 Year Change | -73.84% |
| 5 Year Change | n/a |
| Change since IPO | -77.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.2% |
| 1Y | -21.1% | -17.2% | 8.5% |
Return vs Industry: 0RK underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0RK underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 0RK volatility | |
|---|---|
| 0RK Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 0RK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 0RK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 483 | Dave Hallett | www.exscientia.ai |
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Exscientia plc Fundamentals Summary
| 0RK fundamental statistics | |
|---|---|
| Market cap | €608.29m |
| Earnings (TTM) | -€180.84m |
| Revenue (TTM) | €20.51m |
29.7x
P/S Ratio-3.4x
P/E RatioIs 0RK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RK income statement (TTM) | |
|---|---|
| Revenue | UK£17.07m |
| Cost of Revenue | UK£28.63m |
| Gross Profit | -UK£11.56m |
| Other Expenses | UK£138.95m |
| Earnings | -UK£150.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | -67.74% |
| Net Profit Margin | -881.79% |
| Debt/Equity Ratio | 0.1% |
How did 0RK perform over the long term?
See historical performance and comparison